Wockhardt per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹25.20₹13.12−₹3.02−₹32.05−₹38.79
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹25.19₹13.10−₹3.02−₹32.05−₹38.79
₹304.94₹304.94₹268.70₹218.12₹232.92
₹220.00₹208.21₹185.93₹181.69₹184.10
—₹24.07−₹1.36₹14.22₹10.63
₹15.68₹15.68−₹7.16₹10.39₹7.71
16.216.216.215.414.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

WOCKPHARMA₹1,922.90

Wockhardt Ltd.

· Pharma & Health
₹ CrorePeersBIOCONSYNGENEASTERDMGLANDPPLPHARMACOHANCELALPATHLABNATCOPHARMMcap ₹31,151 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-38.79-32.05-3.0213.1225.20
Diluted EPS-38.79-32.05-3.0213.1025.19
Book Value per Share232.92218.12268.70304.94304.94
Revenue per Share184.10181.69185.93208.21220.00
Cash Flow per Share10.6314.22-1.3624.07—
Free Cash Flow per Share7.7110.39-7.1615.6815.68
Shares Outstanding (cr)14.415.416.216.216.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.